Education
About Us
Working with TipRanks
Follow Us
Mainz Biomed B.V. (MYNZ)
NASDAQ:MYNZ
MYNZ Stock Chart & Stats
$1.16
-$0.30(-6.42%)
At close: 4:00 PM EST
$1.16
-$0.30(-6.42%)
Day’s Range― - ―
52-Week Range$0.55 - $5.34
Previous CloseN/A
Volume20.13K
Average Volume (3M)350.23K
Market Cap
$9.23M
Enterprise Value$4.07M
Total Cash (Recent Filing)$1.91M
Total Debt (Recent Filing)$3.09M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Apr 14, 2026EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.65
Shares Outstanding12,515,336
10 Day Avg. Volume923,862
30 Day Avg. Volume350,228
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.69
Price to Sales (P/S)4.68
P/FCF Ratio-0.24
Enterprise Value/Market Cap0.44
Enterprise Value/Revenue6.16
Enterprise Value/Gross Profit-74.62
Enterprise Value/Ebitda-0.23
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-1.35
Revenue Forecast (FY)$918.00K
Bulls Say, Bears Say
Bulls Say
Clinical ValidationVery strong feasibility results for the pancreatic cancer diagnostic indicate the test may demonstrate reliable clinical performance, supporting further development and boosting scientific credibility.
Commercialization PotentialPromising feasibility data increases the likelihood that the pancreatic diagnostic can advance toward regulatory review and commercialization, representing a potential new revenue stream.
Partnership And Licensing InterestEncouraging pancreatic diagnostic results should enhance attractiveness for licensing deals or collaborations with larger diagnostics firms, which could bring funding and commercialization expertise.
Bears Say
Capital Structure And DilutionA proposed private placement that would concentrate ownership with a single investor and effectively recapitalize the company could cause major share dilution and pressure on the stock.
Product Pipeline And Revenue AssumptionsManagement's decision to stop development of the colorectal screening platform and to exclude those revenues from its model reduces product diversification and eliminates an expected revenue source, heightening execution and valuation risk.
Strategic Direction And Analyst ConfidenceAnalyst downgrades to Hold and removal of a prior price target reflect concerns about the company's strategic shift, increasing investor caution about the near-term outlook.
Mainz Biomed B.V. News
MYNZ FAQ
What was Mainz Biomed B.V.’s price range in the past 12 months?
Mainz Biomed B.V. lowest stock price was $0.55 and its highest was $5.34 in the past 12 months.
What is Mainz Biomed B.V.’s market cap?
Mainz Biomed B.V.’s market cap is $9.23M.
When is Mainz Biomed B.V.’s upcoming earnings report date?
Mainz Biomed B.V.’s upcoming earnings report date is Apr 14, 2026 which is in 27 days.
How were Mainz Biomed B.V.’s earnings last quarter?
Mainz Biomed B.V. released its earnings results on Sep 03, 2025. The company reported -$2.65 earnings per share for the quarter, missing the consensus estimate of N/A by -$2.65.
Is Mainz Biomed B.V. overvalued?
According to Wall Street analysts Mainz Biomed B.V.’s price is currently Overvalued.
Does Mainz Biomed B.V. pay dividends?
Mainz Biomed B.V. does not currently pay dividends.
What is Mainz Biomed B.V.’s EPS estimate?
Mainz Biomed B.V.’s EPS estimate is -1.01.
How many shares outstanding does Mainz Biomed B.V. have?
Mainz Biomed B.V. has 12,515,336 shares outstanding.
What happened to Mainz Biomed B.V.’s price movement after its last earnings report?
Mainz Biomed B.V. reported an EPS of -$2.65 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.775%.
Which hedge fund is a major shareholder of Mainz Biomed B.V.?
Currently, no hedge funds are holding shares in MYNZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mainz Biomed B.V.
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
MYNZ Stock 12 Month Forecast
Average Price Target
―Technical Analysis
―
ENDRA Life Sciences
―
Intelligent Bio Solutions
―
iSpecimen
―
BioNexus Gene Lab Corp
―
Ownership Overview
11.88% Insiders
<0.01% Mutual Funds
8.89% Other Institutional Investors
79.23% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---